Education
About Us
Working with TipRanks
Follow Us
Churchill Capital Corp. XI Class A (CCXI)
NASDAQ:CCXI
CCXI Stock Chart & Stats
$10.18
>-$0.01(-0.10%)
―
--
Day’s Range― - ―
52-Week Range$10.07 - $10.45
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding41,900,000
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Churchill Capital Corp. XI Class A News
CCXI FAQ
What was Churchill Capital Corp. XI Class A’s price range in the past 12 months?
Churchill Capital Corp. XI Class A lowest stock price was $10.07 and its highest was $10.45 in the past 12 months.
What is Churchill Capital Corp. XI Class A’s market cap?
Currently, no data Available
When is Churchill Capital Corp. XI Class A’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Churchill Capital Corp. XI Class A’s earnings last quarter?
Currently, no data Available
Is Churchill Capital Corp. XI Class A overvalued?
According to Wall Street analysts Churchill Capital Corp. XI Class A’s price is currently Undervalued.
Does Churchill Capital Corp. XI Class A pay dividends?
Churchill Capital Corp. XI Class A does not currently pay dividends.
What is Churchill Capital Corp. XI Class A’s EPS estimate?
Churchill Capital Corp. XI Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Churchill Capital Corp. XI Class A have?
Churchill Capital Corp. XI Class A has 41,900,000 shares outstanding.
What happened to Churchill Capital Corp. XI Class A’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Churchill Capital Corp. XI Class A?
Currently, no hedge funds are holding shares in CCXI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Churchill Capital Corp. XI Class A
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California. As of October 20, 2022, ChemoCentryx, Inc. operates as a subsidiary of Amgen Inc.